India to Afghanistan: Amikacin Export Trade Route

To import Amikacin formulations into Afghanistan, the following approvals and registrations are mandatory:

The dossier format aligns with the Common Technical Document (CTD) structure. Timelines for approval can vary; however, applicants should anticipate a processing period of several months. Specific product registration fees are not publicly disclosed and may be obtained directly from the AFDA.

2. Import License: An import license from the Afghanistan Ministry of Public Health is required. This license is contingent upon the successful registration of the product and compliance with all regulatory requirements.

3. GMP Inspection: Indian manufacturing facilities producing Amikacin formulations intended for the Afghan market must comply with GMP standards. The AFDA may require GMP certification from the exporting country's regulatory authority and reserves the right to conduct inspections to verify compliance.

Indian exporters of Amikacin formulations must adhere to the following quality and GMP standards to supply Afghanistan:

1. GMP Certification: Manufacturing facilities must possess a valid GMP certificate issued by the Central Drugs Standard Control Organization (CDSCO) or an equivalent authority. This certification ensures that the facility complies with international manufacturing standards.

2. Product Quality Documentation: Each batch of Amikacin formulations must be accompanied by a Certificate of Analysis (CoA) from an accredited laboratory, verifying the product's quality, purity, and potency.

3. Regulatory Compliance: Exporters must provide a CoPP for each pharmaceutical product, certifying compliance with Indian regulatory standards. Additionally, a Free Sale Certificate (FSC) may be required, confirming that the product is freely marketed in India without restrictions.

As of March 2026, there have been no publicly reported inspections or regulatory actions by the AFDA against Indian pharmaceutical companies exporting to Afghanistan. However, exporters should remain vigilant and ensure continuous compliance with all applicable regulations.

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to Afghanistan:

1. Recognition of Indian Pharmacopoeia: In December 2019, Afghanistan formally recognized the Indian Pharmacopoeia (IP) as a reputable standard for medicines and health products. This recognition facilitates the acceptance of Indian pharmaceutical standards in Afghanistan, streamlining the registration and importation process for Indian exporters.

2. GMP Certification for Local Manufacturers: In May 2025, the AFDA awarded GMP certificates to three Afghan pharmaceutical manufacturers: Snow Pharma, Milli Shifa, and TJL. This initiative aims to enhance domestic pharmaceutical production and may influence the import dynamics, as local manufacturing capabilities improve.

3. Import Alerts: As of March 2026, the U.S. Food and Drug Administration (FDA) has issued several import alerts related to food products from Afghanistan due to contamination concerns. While these alerts primarily pertain to food items, they underscore the importance of stringent quality control measures for all imports, including pharmaceuticals.

Indian exporters should stay informed about these developments and adjust their compliance strategies accordingly to maintain seamless access to the Afghan pharmaceutical market.

As of 2024, Afghanistan's healthcare sector has been expanding, with increased investments in medical infrastructure and services. The demand for antibiotics, including formulations containing Amikacin, is driven by the prevalence of bacterial infections and the need for effective treatment options. While specific market size data for Amikacin formulations in Afghanistan is limited, the country's reliance on imports indicates a significant demand. Domestic pharmaceutical manufacturing capabilities are developing but remain insufficient to meet the total demand, necessitating continued imports of essential medicines.

Afghanistan imposes a 2.5% import duty on pharmaceutical products classified under HS code 30049099, which includes finished formulations containing Amikacin. In addition to the import duty, a 10% Business Receipt Tax (BRT) is applied to imported goods. There are no specific Free Trade Agreements (FTAs) between Afghanistan and India that provide preferential tariff rates for pharmaceutical imports. Currently, there are no anti-dumping duties imposed on pharmaceutical imports from India.

India is a major supplier of pharmaceutical products to Afghanistan, including formulations containing Amikacin. Other significant suppliers include Pakistan and China. India's share of Afghanistan's total imports of Amikacin formulations is substantial, reflecting strong trade relations and India's competitive pricing. Indian pharmaceutical products are generally priced competitively compared to those from China and European Union manufacturers, making them a preferred choice for Afghan importers.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. This extensive manufacturing capability extends to finished dosage forms containing Amikacin, including injections, which are produced at scale to meet both domestic and international demand. The country's cost-effective production is driven by economies of scale, competitive labor costs, and a well-established supply chain for pharmaceutical ingredients. As of October 2023, India had 134 FDA-registered facilities for finished dosage forms, underscoring its commitment to quality and regulatory compliance.

When comparing Amikacin formulations from India, China, and the European Union, several factors come into play:

• Cost: Indian manufacturers offer Amikacin formulations at competitive prices due to lower production costs and economies of scale. Chinese products are often priced similarly but may face higher shipping costs and longer lead times. European formulations, typically branded generics, are priced higher due to stringent regulatory standards and higher production costs.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for producing high-quality generics, with many facilities approved by international regulatory bodies such as the FDA and WHO. Chinese manufacturers have made significant strides in quality but may still face skepticism in certain markets. European manufacturers are generally perceived as high-quality producers, albeit at a higher cost.

• Regulatory Acceptance in Afghanistan: Afghanistan's regulatory framework is more aligned with Indian and European standards, facilitating smoother import processes for products from these regions. Chinese products may require additional documentation and scrutiny.

• Supply Reliability: Indian manufacturers have a proven track record of reliable supply chains, with established logistics routes to Afghanistan. Chinese suppliers may face logistical challenges and longer delivery times. European suppliers offer reliability but at higher costs and potentially longer lead times.

The India-Afghanistan supply chain for Amikacin formulations is robust, supported by India's substantial manufacturing capacity. Indian facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and FDA approvals. While specific capacity constraints among top Indian manufacturers are not evident, the industry continues to expand to meet growing global demand.

For Afghan buyers sourcing Amikacin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Familiarize yourself with common payment terms in India-Afghanistan pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to establish mutually beneficial agreements.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory approvals, and assessment of quality control systems, to ensure supplier reliability.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Afghan regulatory requirements to facilitate smooth importation and distribution processes.

1. Verify Manufacturer Registration with AFDA: Confirm that the Indian manufacturer is registered with the Afghanistan Food and Drug Authority (AFDA) as per the "Company Registration Guideline-English" provided by AFDA.

2. Assess Validity of GMP Certification: Ensure the manufacturer holds a valid Good Manufacturing Practice (GMP) certificate, in line with WHO guidelines, to confirm adherence to quality standards.

3. Review Product Registration Status: Check that the specific Amikacin formulation is registered with AFDA, following the "Medicine Registration Guideline-English" outlined by AFDA.

4. Evaluate Quality Management Systems: Assess the manufacturer's quality management systems to ensure they meet international standards, including compliance with Good Distribution Practices (GDP) and Good Storage Practices (GSP).

5. Confirm Regulatory Compliance: Verify that the manufacturer complies with the regulatory requirements of both the exporting (India) and importing (Afghanistan) countries, including adherence to the Drugs and Cosmetics Act of 1940 and the Drugs and Cosmetic Rules of 1945.

6. Conduct Risk Assessment: Perform a risk assessment of the supplier, considering factors such as historical compliance, market reputation, and previous audit outcomes.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for verifying the authenticity and origin of the pharmaceutical product.

3. Good Manufacturing Practice (GMP) Certificate: Issued by the relevant regulatory authority, this certificate confirms that the manufacturing facility complies with GMP standards.

4. Stability Data: Includes data on the product's stability under various environmental conditions, ensuring it remains effective throughout its shelf life.

5. Batch Manufacturing Records: Detailed records of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): A comprehensive document submitted to regulatory authorities, containing detailed information about the manufacturing, processing, packaging, and storage of the drug.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organization (CDSCO), this certificate indicates that the product is freely sold in the country of origin and meets regulatory standards.

8. Insurance Certificates: Documents that provide coverage details for product liability, ensuring protection against potential claims related to product defects.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies such as the FDA or WHO, indicating compliance issues.

2. Suspension of GMP Certification: Any suspension or revocation of GMP certification suggests significant quality management failures.

3. Unrealistically Low Pricing: Prices significantly below market rates may indicate potential compromises in product quality or authenticity.

4. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

5. Limited Export History: Absence of a track record in exporting to regulated markets may reflect inexperience or potential quality issues.

6. Resistance to Audits: Hesitation or refusal to allow facility audits suggests possible non-compliance with regulatory standards.

1. Pre-Audit Desktop Review: Conduct a thorough review of the manufacturer's documentation, including licenses, certifications, and previous audit reports.

3. Post-Audit Corrective Actions: Require the manufacturer to address any identified deficiencies within a specified timeframe and provide evidence of corrective actions taken.

4. Annual Re-Qualification Process: Implement a yearly review of the supplier's compliance status, including updated audits and documentation reviews.

5. Remote Monitoring Options: Utilize virtual audits, regular reporting, and third-party inspections to maintain ongoing oversight of the supplier's operations.

6. Cost Estimates and Timeline: Budget approximately $5,000 to $10,000 USD for an on-site audit, with the process typically taking 2-3 days, excluding travel time.

By adhering to this structured approach, Afghan pharmaceutical companies can ensure that their Indian Amikacin suppliers meet the necessary quality and regulatory standards, thereby safeguarding public health and maintaining compliance with both national and international regulations.